Page 4 - பதில் ரேட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Fler elever får nu undervisning på plats i skolan
aftonbladet.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aftonbladet.se Daily Mail and Mail on Sunday newspapers.
Fler elever är tillbaka i klassrummen
arbetarbladet.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arbetarbladet.se Daily Mail and Mail on Sunday newspapers.
Pr-konsulten Edit Künstlischer läxar upp journalisterna: Sänk garden!
resume.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from resume.se Daily Mail and Mail on Sunday newspapers.
Pr-konsulten Edit Künstlicher läxar upp journalisterna: Sänk garden!
resume.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from resume.se Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
WALTHAM, Mass., April 20, 2021 /PRNewswire/ Syndax Pharmaceuticals, Inc. ( Syndax, the Company or we ) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company s highly selective, oral menin inhibitor. Information on how to access the live video webcast and accompanying slide presentation can be found below. Data reported today further support the potential for SNDX-5613 to induce clinically meaningful responses in patients with genetically-defined acute leukemias, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. Notably, robust clinical activity, including multiple complet